Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients
The purpose of the study is to evaluate the efficacy and safety of the combination of cytotoxic chemotherapy (Oxaliplatin and 5Fu) with bevacizumab concomitantly with radiotherapy as neoadjuvant treatment for patients with locally advanced but resectable rectal adenocarcinoma.
Rectal Adenocarcinoma
DRUG: Bevacizumab|DRUG: Oxaliplatin|DRUG: 5-FU|RADIATION: Radiotherapy
Pathological complete response rate, one year
Time to progression, one year|Time to relapse, one year|Overall survival, one year|Safety data of this regimen, one year
Primary endpoint: Pathological Complete Response Rate (pCR)

Secondary endpoint: Time to Relapse, disease free survival, overall survival and safety data